First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
Executive Summary
Agency memo on manufacturer communications about unapproved uses says new court rulings and studies on off-label uses and adverse reactions support restrictions; whether agency’s new leadership has the same view remains to be seen.
You may also be interested in...
Off-Label Guidance Creates ‘Safe Harbor’ For Dissemination of Certain Info To HCPs
The FDA's revised draft guidance on scientific communications to health care providers about unapproved uses of products describes the studies that are likely to be scientifically sound and clinically relevant. The agency also gives recommendations on presenting off-label information on web pages and in exhibit halls.
FDA Creates Division To Support First Amendment Policy Development, Oversee Advertising Research
Multiple unfavorable court decisions have forced the agency to adjust its advertising enforcement strategies.
Off-Label Use Final Rule: US FDA Declines To Focus Solely On Promotional Claims
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.